诺和诺德公司投资1.3亿美元建立新的糖尿病实验室

诺和诺德公司（丹麦著名的制药公司）计划投资1.3亿美元在丹麦的研发中心建立新的糖尿病实验室。该项目的建筑已经开始动工，被称为“ Diabetes Research House”。公司相关负责人称，该研究中心将于2016年投入使用，并可容纳大约350名员工。该项目也将产生超过1000个工作岗位。

工程占地面积16500平方米，分为三个部分：包括二个科研楼和一个行政大楼。行政楼将有一个可容纳450人的礼堂。诺华诺德的执行副总裁Mads Krogsgaard Thomsen在一份声明中表示，该平台将为糖尿病研究创造更全面的生化和蛋白技术研究技术环境，同时与丹麦以及海外的I,II型糖尿病临床治疗的著名科学家密切合作。

除此以外，诺华诺德也在世界其他地方拓展研究中心。九月，诺华诺德计划在西雅图建立新的肥胖研究中心。（转化医学网360zhyx.com）

原文：Novo Nordisk Invests $130M in New Diabetes Lab Facility

Novo Nordisk is investing around DKK 750 million ($130 million) in new laboratories at the firm's R&D campus in Måløv, Denmark. Construction is already underway for the new facility, dubbed DiabetesResearch House, which Novo Nordisk says will accommodate around 350 employees and should be ready for occupation in early 2016. The firm also expects the project to generate over 1,000 jobs outside Novo Nordisk during the construction phase.

With floor space of 16,500 square meters distributed on three stories, Diabetes Research House will have two laboratory wings, a middle building with office space, and an auditorium seating 450 people. Mads Krogsgaard Thomsen, Ph.D., Novo Nordisk's evp and CSO, said in a statement that the facility will provide an environment for diabetes research within biotechnology and protein chemistry.

"Here [at the facility] our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes," Dr. Thomsen commented.

The Danish firm is expanding in other parts of the world, too: In September it announced plans to establish a new obesity research unit in Seattle, WA.